See other companies on Welcome to the Jungle
Atomwise
AI systems for drug discovery
- 21-100 employees
- Healthcare
- B2B
- Artificial Intelligence
- Machine Learning
- MedTech
- Yerba Buena, San Francisco, CA
Jump to section
Company mission
To make better medicines, faster.
-31% employee growth in 12 months
Our take
AI has become a critical tool to advance the pace and complexity of new drug discovery. It’s an emerging sector that’s attracted steep VC investment, with different startups applying the technology to different areas of pharmaceutical research. Preclinical pharma company Atomwise is focusing on structure-based small molecule discovery.
Focusing on more than 600 disease targets with 250+ global partners, the company has already had success. It’s also developing a wholly-owned drug discovery pipeline in co-development with X37, and partners with biopharma companies like Bayer and GC Pharma and researchers at institutions like Toronto and Duke universities.
The emerging, urgent, and relatively specialist sector of AI assisted discovery has made for a cash rich and relatively non-competitive market. Terray Therapeutics, Owkin, and Hoxton Ventures are just a few of the startups using varying methods in varying areas of pharma specialisation, all of which are raking in hundreds of millions in VC investment. So there’s a lot to play for, and Atomwise has carved out a strong and leading niche for itself that lays a strong foundation for future growth
Kirsty
Company Specialist at Welcome to the Jungle
Benefits
- Flexible work schedule
- Generous parental leave
- Competitive salary, commensurate with experience
- Stock compensation plan – you’ll be an Atomwise co-owner
- Platinum health, dental, and vision benefits
- 401k with 4% match
- Strong emphasis on collaborative learning and career development
Company values
- Collaborative
- Academic Environment
- Data Driven
- Innovative
- Opportunities for Growth
- Inclusive
- Family-Oriented
- Professional and Supportive Colleagues
Funding (last 2 of 6 rounds)
Oct 2020
$2.3m
GRANT
Aug 2020
$123m
SERIES B
Total funding: $176.7m
This company has top investors
Leadership
Abraham Heifets
(CEO)Took up various Software Engineer roles at IBM, prior to completing a PhD in Computer Science at the University of Toronto.
Izhar Wallach
(CTO)Worked as System Admin at Intel, then an Algorithm Developer at Keddem Bioscience Ltd., before completing a Computer Science PhD at the University of Toronto.